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Abstract
Background: Urinary tract infections (UTI) are common in clinical practice and empirical treatment is largely
employed due to predictability of pathogens. However, variations in antibiotic sensitivity patterns do occur, and
documentation is needed to inform local empirical therapy. The current edition of the Uganda Clinical Guidelines
recommends amoxicillin or cotrimoxazole as choice drugs for empirical treatment of community-acquired UTI.
From our clinical observations, we suspected that this recommendation was not effective in our setting. In order to
examine validity, we sought to identify bacteria from community-acquired infections and determine their
susceptibility against these antibiotics plus a range of potentially useful alternatives for treatment of UTI.
Methods: A cross-sectional study of mid-stream urine collected from 339 symptomatic patients over a three-month
period at Gulu regional referral hospital. Qualitative culture and identification of bacteria and antibiotic sensitivity
testing using the modified Kirby-Bauer disk diffusion method was done. Participants’ demographic and clinical
characteristics were collected using a standard form. Results were analyzed by simple proportions among related
variables and confidence intervals computed using binomial exact distribution.
Results: Eighty two cultures were positive for UTI. Staphylococcus spp (46.3%) and Escherichia coli (39%) were the
most common pathogens. There was high resistance to cotrimoxazole (73.2%), nalidixic acid (52.4%) and amoxicillin
(51.2%). The most favorable antibiograms were obtained with gentamicin, amoxicillin-clavulanate and levofloxacin
where 85.4%, 72.0%, 67.1% of isolates respectively, were either sensitive or intermediate. Only 51% of isolates were
sensitive to ciprofloxacin.
Conclusion: There was high resistance to most antibiotics tested in this study. The recommendations contained in
the current edition of the Uganda Clinical Guidelines are not in tandem with antibiotic sensitivity pattern of
uropathogens seen in our setting. Amoxicillin-clavulanate or gentamicin should be considered for replacement of
amoxicillin and cotrimoxazole for empirical treatment of UTI in our setting.
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Background
Urinary tract infections (UTI) are a common medical
problem encountered in medical practice. Females are
more prone to infection than males, a phenomenon
explained by their short urethra and its anatomical prox-
imity to the anal orifice [1,2]. Because uropathogens
largely originate from colonic flora [3], they are easy to
predict. This is the rationale for empirical treatment in
community-acquired urinary tract infections (CA-UTI)
[1,4]. However, empirical treatment limits opportunities
for surveillance of antibiotic resistance among pathogens
that cause community-acquired UTI. If regularly updated
to match changing susceptibility patterns, empirical treat-
ment is also a convenient strategy for effective resource
utilization. This is especially true in developing countries
where resource constraints mean that it is often impracti-
cal to routinely perform antibiotic sensitivity tests [5]. Re-
ports of uropathogens resistant to previously effective
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antibiotics have emerged globally in recent years [6-18].
The situation is especially dire in Africa where irrational
antibiotic practices are common [18]. Variations in anti-
biotic resistance patterns are known to occur across differ-
ent geographical regions, even within the same country
[16,19]. Such variations must be well documented so as to
inform local empirical treatment as well as foster rational
antibiotic use.
The current edition of the national treatment guidelines
in Uganda recommends the use of amoxicillin or
cotrimoxazole for empirical treatment of CA-UTI [20].
However, based on our clinical experience at Gulu re-
gional hospital, we suspected that resistance to these anti-
biotics was possibly high. Therefore, continued empirical
use was likely to increase chances of treatment failure,
leading to unnecessary patient suffering and increased
healthcare costs in the long run. The broad aim of this
study was to examine the validity of the current recom-
mendations for empirical treatment of CA-UTI as per the
national guidelines. Specifically, we set out to identity
uropathogens from community-acquired infections at
Gulu regional hospital and thereafter, determine their re-
sistance profiles against the currently recommended anti-
biotics. In addition, we sought to determine resistance
profile against a range of potentially useful alternatives for
treatment of CA-UTI in our setting.
Methods
Study design
This was a cross-sectional study employing both qualita-
tive and quantitative methods. All outpatients (≥18 yrs)
with symptoms suggestive of a UTI were consecutively
recruited into the study. Symptoms of interest included
supra-pubic pain, a burning sensation while voiding
(dysuria), urine frequency and urge incontinence. A pre-
designed standard form was used to record relevant
socio-demographic and medical history information, as
well as important clinical and laboratory findings. Partic-
ipants were asked to provide an on-the-spot urine sam-
ple for investigation to determine true cases of UTI.
Bacterial isolates from true infections were identified
and subjected to antibiotic susceptibility testing using
the Kirby-Bauer disk diffusion method [21]. The
recommended antibiotics, plus a range of potentially
useful alternatives were included in the tests which were
performed at the microbiology laboratory of the Faculty
of Medicine, Gulu University.
Urine sample collection
Mid-stream (clean-catch) urine samples were collected by
participants under the supervision of nurses and midwives
serving as research assistants. These were trained on how
to instruct and guide urine collection as per standard
methods [22]. Mindful of the cultural sensitivity of the
procedure, we employed research assistants who were
conversant with the local Luo dialect and cultural experi-
ence. Participants were led into a clean toilet facility and
asked to wash their hands with soap and water prior to
urine collection. They were handed a well-labeled, sterile,
wide mouth urine container (50 ml) and accordingly
instructed. Labeling consisted of participant study num-
ber, sex, and date of urine collection. Briefly on the collec-
tion method, the uncircumcised male was told to retract
the foreskin on the glans penis prior to collection. He was
asked to void the first bit of urine into the toilet pan be-
fore collecting the mid-portion (starting approximately 2 s
from beginning of flow) and then finally voiding the last
bit again into the toilet pan. He then closed the bottle and
passed it on to the research assistant for storage. In the
case of females, the research assistant gently separated the
labia minora and wiped the area around the urethral ori-
fice (from front to back) using sterile gauze dipped in nor-
mal saline. This procedure was repeated with the labia
held apart before collection of urine as described above.
All samples were immediately stored in an ice box and
transported to the laboratory within three hours of
collection.
Determination of true infection and identification of
uropathogens
Urine samples were registered in the record book and
given serial laboratory numbers. The consideration of a
sample as ‘true UTI’ was arrived at in a two-stage
screening process involving microscopic enumeration of
urine leucocytes followed by quantitative urine culture.
This approach was adopted because neither approach
alone was considered sufficient to conclusively label a
case as ‘true UTI’. For instance, urinary schistosomiasis
or prior antibiotic use, were likely to confound findings
from the above methods respectively. First, one microliter
(1 μL) of a well mixed urine sample was aspirated into an
improved Neubauer counting chamber (Marienfeld-
GmbH, Germany) and examined with a light microscope
under X 400 magnification. A finding of at least 5 and 10
leucocytes per microliter in males and females respectively
was considered UTI basing on previous recommendations
[23]. All samples that were positive by this criterion were
further subjected to urine culture in the second stage. A
10 μL plastic loop was used to pick a well mixed urine
sample which was plated for quantitative culture on Nu-
trient Agar (BioMerieux/Hi Media) and CLED Agar (BD
Diagnostic Systems, Germany) prepared according to
standard methods [24]. The use of two media was aimed
at isolating all possible bacteria as well as using their
unique colony growth characteristics to aid identification.
All plates were inverted and incubated at 35°C (± 1) for 18
to 24 hours with each resultant colony considered to rep-
resent 100 CFU/ml. A cutoff point of 105 CFU/ml was
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considered significant growth as long as the culture
was pure [24]. All urine samples that had significant
leucocyturia and thereafter significant bacterial growth
were considered true UTI. In addition, samples that
had significant leucocyturia but less than 105 CFU/mL
were considered true UTI if there was a positive his-
tory of antibiotic use prior to presenting at the hos-
pital. Unique colony growth characteristics, gram staining
and a battery of biochemical tests were used to identify
uropathogens. These included sugar fermentation using
TSI agar, litmus milk decolorization, citrate utilization, in-
dole production, the methyl red test, as well as catalase,
coagulase and urease tests. All tests were performed
according to standard methods described elsewhere [24].
Preparation of Mueller-Hinton agar and antibiotic
susceptibility assays
Antibiotic susceptibility was done on Mueller-Hinton II
agar (Oxoid, UK) according to the Kirby-Bauer method
modified in accordance with current guidelines from the
Clinical & Laboratory Standards Institute (CLSI) [25].
Preparation of Mueller-Hinton II agar was by dissolving
38 g/L as per manufacturer’s recommendations. All agar
preparations were fully dissolved and autoclaved at 121°C
for 15 minutes. After sterilization, 25 ml was gently
poured onto each sterile petri dish (90 mm diameter)
placed on a horizontal work top and allowed to cool to
room temperature. This corresponds to an agar depth of
4 mm [24]. The plates were then inverted and stored in
sealed plastic bags at 4–8°C until use, in any case not lon-
ger than 15 days. Quality control of each batch was en-
sured by testing Enterococcus faecalis (ATCC 2922)
against cotrimoxazole. Prior to inoculation and placement
of antibiotic disks, sterility of each plate was ensured by
overnight incubation (35 ± 1°C) in which no growth
occurred.
Three to five morphologically similar colonies of each
organism (aged 18–24 h) were touched with a sterile
loop and inoculated in 4 ml of peptone water (BDH
Chemicals Ltd) prepared according to manufacturer’s
recommendations. The peptone water was incubated at
36°C for 2 to 5 hours until turbid, and standardized to
0.5 McFarland nephelometer prepared by dissolving
1 gram of barium chloride in 100 ml of sulfuric acid
using normal saline. The entire surface of agar was inoc-
ulated by swabbing and allowed to dry for 3 to 5 minutes
before aseptically placing 4 antibiotic disks per plate.
The following commercially prepared antibiotic disks
(Oxoid, UK) were used: nitrofurantoin (50 μg), nalidixic
acid (30 μg), ciprofloxacin (5 μg), levofloxacin (5 μg),
amoxicillin (10 μg), cephalexin (30 μg), amoxicillin-
clavulanate (20/10 μg), cotrimoxazole (25/125 μg), gen-
tamicin (10 μg), azithromycin (15 μg) and oxacillin
(10 μg). Well set plates were incubated in a dry oven
maintained at 35°C (±1°C). Inhibition zone diameters
were read at 18 h for all organisms except for
Staphylococcus which was read at 24 h. Clear zone di-
ameters were measured to the nearest millimeter using
a millimeter ruler under natural light. Internal quality
control was ensured by incubating Staphylococcus aur-
eus (ATCC 25923) and Escherichia coli (ATCC 25922)
strains under the same conditions.
Data entry and analysis
Laboratory entries were made in a laboratory book each
day. The data was constantly checked for completeness
and cleaned during the study. Each measurement of the
inhibition zone diameter was interpreted as ‘sensitive’,
‘intermediate’ or ‘resistant’ according to CLSI standard
interpretative charts [25]. At the end of collection, data
was double-entered into Epidata® computer program,
validated and analyzed by simple percentages among re-
lated variables. For all proportions obtained, confidence
intervals set at 95% level of significance were computed
using binomial exact distribution.
Ethical considerations
The study was performed in accordance with the
Helsinki Declaration and was approved by the Institu-
tional Review Board of the Faculty of Medicine, Gulu
University (reference no. GU/IRB/03/06/11). Permission
to conduct the study was granted by the Uganda Na-
tional Council for Science and Technology. Informed
consent was obtained in writing from each participant.
The investigators ensured that participants were handled
in a professional and culturally sensitive manner and pa-
tient confidentiality was observed throughout the study.
At the earliest opportunity, clinically important informa-




Out of 339 samples analyzed over a period of three
months (June to August, 2011), only 82 met our inclu-
sion criteria for true UTI. Three samples (3.7%) were
obtained from males while seventy nine (96.3%) came
from females. Fourteen women (17.7%) were pregnant
and one male participant had clinical findings consistent
with prostatic hypertrophy. Sixty nine participants
(20.4%) reported antibiotic use prior to presenting at the
hospital. Most of them (72%) had self-medicated and
none had received a full antibiotic course by the time of
presentation to the hospital. Table 1 gives a summary of
the demographic and clinical characteristics of patients
investigated in the study.
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Identity and proportions of uropathogens isolated
As shown in Table 2, Staphylococcal species (n = 38,
46.3%) caused majority of UTI. This was followed by
Escherichia coli (n = 32, 39%). Other uropathogens iso-
lated include Enterococcus faecalis (n = 6, 7.3%), Klebsiella
pneumoniae (n = 4, 4.9%) and Proteus mirabilis (n = 2,
2.4%). Among the Staphylococcal species isolated, 28 were
identified as S. saprophyticus while 9 were identified as
S. aureus. There was one case of S. epidermidis iso-
lated from the male patient with prostatic hypertrophy.
Antibiotic susceptibility and resistance profiles
Regarding antibiotic susceptibility assays, the zone diame-
ters with all control strains were within published limits.
As presented in Table 2, there was widespread resistance
among all uropathogens to cotrimoxazole, amoxicillin,
nitrofurantoin and nalidixic acid. A summary of the rela-
tive proportions of susceptibility and resistance profiles
from all uropathogens against each antibiotic is presented
in Table 3 along with their confidence intervals set at 95%
level of significance. When sensitive and intermediate
readings were combined, the most favorable profiles were
obtained with gentamicin, amoxicillin-clavulanic acid and
levofloxacin for which 85.4%, 72.0% and 67.1% of isolates
respectively, were considered susceptible (Table 3). Of the
pathogens isolated from male participants, there was one
case each, of Escherichia coli, Staphylococcus aureus and
Staphylococcus epidermidis. For the entire study, this was
the only incidence of Staphylococcus epidermidis. This
participant also had symptoms of prostatic hypertrophy.
Interestingly as shown in Table 4, this organism had
marked sensitivity to most antibiotics tested except nali-
dixic acid and nitrofurantoin.
Table 1 Demographic and clinical characteristics of
outpatients with urinary tract infection at Gulu regional
hospital (n = 82)
Parameter Males
(n = 3)
Females (n = 79) Total (%)
Mean age in years (range) 46 (37–59) 23 (18–70)
Pregnancy status among
participants




Increased urine frequency - 85 N/A
Supra pubic pain/discomfort - 77 N/A
Dysuria - 68 N/A
Urge incontinence - 55 N/A
History of recurrent symptoms








Renal angle pain/tenderness 0 0 0
Prostatic enlargement 1 N/A
Recent catheterization 0 0 0
Positive urine sugar 0 0 0
Recent antibiotic use
(2 weeks)b
0 69 69 (20.4)
Significant leucocyturia
(pyuria)b
3 115 118 (34.8)
At least 105 CFU/mLc 3 64 67 (56.8)
Key: N/A, Not applicable; CFU, Colony forming units. a calculations only done
for female participants as males were too few for meaningful results.
b recorded from all patients having any symptom suggestive of a UTI (n = 339).
c test performed only on patients with significant leucocyturia (n = 118).
Table 2 Susceptibility profile of uropathogens isolated from symptomatic outpatients at Gulu regional hospital,
northern Uganda (n = 82)
Uro-isolates Staphylococcus spp. n = 38 E. coli n = 32 Klebsiella spp. n = 4 P. mirabilis n = 2 E. faecalis n = 6
Antibiotic disks S I R S I R S I R S I R S I R
Nitrofurantoin (50 μg) 8 14 16 10 5 17 0 1 3 0 0 2 4 0 2
Nalidixic acid (30 μg) 4 10 24 13 6 13 0 2 2 0 0 2 2 2 2
Cotrimoxazole (25/125 μg) 5 5 28 5 5 22 0 0 4 0 0 2 2 0 4
Amoxicillin (10 μg) 16 6 16 10 3 19 0 1 3 0 2 0 2 0 4
Amoxi/clav (20/10 μg) 26 3 9 10 10 12 0 4 0 0 2 0 3 1 2
Cephalexin (30 μg) 16 13 9 5 8 19 3 1 0 0 0 2 2 0 4
Ciprofloxacin (5 μg) 24 0 14 19 5 8 3 1 0 2 0 0 4 0 2
Levofloxacin (5 μg) 29 2 7 13 9 10 2 2 0 2 0 0 3 1 2
Gentamicin (10 μg) 24 7 7 26 1 5 4 0 0 2 0 0 6 0 0
Azithromycin (15 μg) 6 9 23 10 17 5 4 0 0 1 1 0 5 1 0
Oxacillin (10 μg)* 7 0 2 - - - - - - - - - - - -
Key: S, Sensitive; I, Intermediate; R, Resistant; * tested on Staphylococcus aureus only (n = 9).
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Discussion
This study revealed relatively high frequencies of resistance
to most antibiotics tested. Resistance to cotrimoxazole,
amoxicillin, nitrofurantoin and nalidixic acid were particu-
larly alarming. This is consistent with our clinical observa-
tions as well as findings from other recent studies done in
Uganda [14,26,27]. Such high levels of resistance are prob-
ably due to antibiotic misuse by poorly trained health
workers as has been documented in many developing
countries [18,28,29]. In addition, weak government regula-
tion allows for the importation and sale of substandard
drugs, often from unlicensed outlets. This encourages
domiciliary self-medication practices that have become
commonplace in Uganda [30,31]. Moreover, it is not un-
common for unqualified health workers to offer clients the
option of purchasing small quantities of antibiotics. This
leads to inadequate dosing resulting into sub-inhibitory tis-
sue concentrations that facilitate selection of antibiotic-
resistant strains. It has been observed that the motives for
antibiotic misuse by health workers are similar to those for
misuse by lay persons: to cut costs and act expeditiously to
treat suspected bacterial infections [28].
The particularly high resistance to cotrimoxazole may
be explained by additional factors common in our set-
ting. These include the use of cotrimoxazole as prophy-
laxis among HIV positive patients [20] and the use of
sulfadoxine-pyrimethamine (shares enzyme targets with
cotrimoxazole) for routine malaria prophylaxis during
pregnancy [20]. In light of these considerations, we
strongly suspect that a similar resistance profile occurs
in other parts of Uganda. Therefore, UTI treatment with
cotrimoxazole is likely to fail, exposing patients to un-
necessary distress and an increased risk of complica-
tions. Some authors have however questioned the
predictive value of in-vitro resistance testing among
uropathogens, especially for antibiotics that achieve
urinary concentrations much higher than those tested in
laboratory assays [6,32]. For instance, it has been
reported that urine levels of trimethoprim and sulfa-
methoxazole are 35 and 3 times, respectively, the levels
in serum [33]. In such cases, it is possible that even with
apparent in-vitro resistance, successful cure may be real-
ized. In the present context, this issue may require fur-
ther investigation.
Nearly 50% of uropathogens (40/82) were resistant to
ciprofloxacin (Table 3). This is far above the 20% rate
recommended for empirical use of antibiotics for
community-acquired UTI [34,35]. Ironically, a 32% re-
sistance was found with levofloxacin yet this antibiotic
has barely been used in our setting owing to prohibitive
costs. A fluoroquinolone cross-resistance phenomenon
may explain this finding since the two drugs also share
an enzyme target. These findings are of great concern
considering that fluoroquinolones are reserved for severe
Table 3 Relative proportions of susceptibility and resistance profiles from all uropathogens isolated from outpatients
at Gulu regional hospital, northern Uganda (n = 82)
Antibiotic (disc potency) Sensitive (95% CI) Intermediate (95% CI) Total a (%) Resistant (95% CI)
Nitrofurantoin (50 μg) 24 (19.5-40.4) 20 (15.6-35.1) 44 (53.7) 38 (35.3-57.7)
Nalidixic acid (30 μg) 19 (14.7-33.8) 20 (15.6-35.1) 39 (47.6) 43 (41.1-63.6)
Cotrim.b (25/125 μg) 12 (7.8-24.2) 10 (6.0-21.3) 22 (26.8) 60 (56.2-82.4)
Amoxicillin (10 μg) 29 (25.1-46.7) 11 (6.9-22.7) 40 (48.8) 42 (39.9-62.4)
Amox-clav c (20/10 μg) 39 (36.4-58.9) 20 (15.6-35.1) 59 (72.0) 23 (18.7-39.1)
Cephalexin (30 μg) 26 (21.9-42.9) 22 (17.6-37.8) 48 (58.5) 34 (30.7-52.9)
Ciprofloxacin (5 μg) 36 (33.0-55.3) 6 (2.7-15.2) 42 (51.2) 40 (37.6-60.1)
Levofloxacin (5 μg) 44 (42.3-64.7) 11 (6.9-22.7) 55 (67.1) 27 (22.9-44.2)
Gentamicin (10 μg) 62 (57.4-84.4) 8 (4.3-18.3) 70 (85.4) 12 (7.8-24.2)
Azithromycin (15 μg) 26 (21.9-42.9) 28 (24.0-45.4) 54 (65.9) 28 (24.0-45.4)
Key: a sum of sensitive and intermediate readings, b cotrimoxazole, c amoxicillin-clavulanic acid.
Table 4 Susceptibility profiles of uropathogens isolated from male patients at Gulu regional hospital, northern Uganda
(n = 3)
Uropathogen TS AX CL NI NA CIP LEV CN AZM AMC OX*
S. epidermida S S S R R S S S I S
S. aureus R R S I R R R S R S S
E. coli R R I S S S R R S R -
Key: S, Sensitive; I, Intermediate; R, Resistant; TS, Cotrimoxazole; AX, Amoxicillin; AZM, Azithromycin; CL, Cefalexin; NI, Nitrofurantoin; NA, Nalidixic acid; CIP,
Ciprofloxacin; LEV, Levofloxacin; CN, Gentamicin; AMC, Amoxicillin-clavulanic acid; OX, Oxacillin, a Staph. epidermidis was associated with prostatic
hypertrophy, * tested on Staphylococcus aureus only.
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or complicated UTI in Uganda [20]. Our study found a
46% resistance to nitrofurantoin (38/82, Table 3) com-
pared to that of Mwaka et al., where only 2% of isolates
were reported resistant among non-pregnant women in
Kampala [26]. This apparent disparity might have come
from the use of nitrofurantoin disks of different potency
(300 μg in Mwaka et al., and 50 μg in ours). In addition,
socio-demographic differences between the population
in Kampala and Gulu (approximately 400 kilometers
apart) might have contributed. Being urban and rural
populations respectively, differences in lifestyles, occupa-
tion, culture, attitudes and literacy exist. These factors
(along with genetics) are known to influence disease and
health seeking patterns, and may explain geographical
variations in antibiotic resistance even within the same
country [16,19].
The most favorable antibiograms were obtained with
gentamicin and amoxicillin-clavulanic acid where a total
of 85.4% and 72.0% of isolates respectively, were either
sensitive or intermediate against all organisms (Table 3).
Either of these antibiotics could replace the current
choices for empirical treatment of community-acquired
UTI in our setting. Gentamicin is quite affordable and is
already available within our public hospitals. To mitigate
toxicity concerns, our physicians have adopted the newer
once daily dosing of gentamicin known to be safer yet as
effective as multiple dosing schedules [36]. An important
drawback however is the fact that gentamicin has to be
administered exclusively by injection, and a move to-
wards its adoption is likely to be material and labor in-
tensive. We fear that a resource-constrained healthcare
system like ours will be particularly sensitive to add-
itional strain. On the other hand, the high cost of oral
amoxicillin-clavulanate means that it may not be avail-
able to all those who need it within the public sector.
At 46.3%, Staphylococcal species formed the majority
of uropathogens isolated in our study. This was followed
by Escherichia coli at 39%. This pattern is slightly differ-
ent from that seen in most literature, where Escherichia
coli commonly predominates [6-13]. Our findings are
however similar to those reported by Kyabaggu et al.
[14], where Staphylococcal species (32%) followed by
Klebsiella (21%) were the commonest uropathogens iso-
lated among patients at a metropolitan hospital in
Kampala. Two other studies done at Mulago national re-
ferral hospital in Kampala ranked Staphylococcal species
second to Escherichia coli among leading causes of
asymptomatic bacteriuria among pregnant and non-
pregnant women [26,27]. In our study, most Staphylo-
coccal infections were due to S. saprophyticus (28/38).
This organism has generally been found to colonize the
urinary tract of sexually active women [37,38]. Our find-
ings may point in this direction and are implicitly sup-
ported by the young study population and the fact that
Uganda has one of the highest fertility rates in the world
[39]. With a mean age 23 years, female participants in
our study were much younger than female participants
in a similar European study (mean age 51.6) published
recently [40]. Looking at these two populations, differ-
ences in sexual patterns that may influence UTI etiology
are likely to exist.
This study presents outpatient-based antibiograms of
uropathogens isolated from consecutively selected par-
ticipants presenting to Gulu regional hospital. This rep-
resents a fairer picture of antibiotic susceptibility profiles
within this community than would be expected from
inpatient-based (or laboratory-based) antibiograms. The
latter are more likely to reflect a selection bias towards
complicated UTI and therefore, to over-estimate resist-
ance prevalence in a particular community [32]. In this
study, the proportion of samples that turned out as true
UTI was rather small (82/339) compared to the partici-
pant number that were recruited with symptoms. The
poor correlation between symptoms and positive diagno-
sis may be explained by the rampant tendency among
patients to self-medicate and only visit hospitals when
symptoms persist. In such cases, quantitative urine cul-
ture is likely to be less sensitive, leaving investigators
with a diagnostic dilemma. Consequently, our decision
to adhere to the 105 CFU/mL cut-off value might have
excluded a significant proportion of UTI cases. In
addition, the decision to consider as contaminants, all
suspected cases where two or more organisms were iso-
lated might also have contributed to the low numbers
observed. Nevertheless, we were able to isolate most
species commonly associated with community-acquired
UTI in reasonable proportions. As shown in Table 1,
some urine samples with leucocyturia did not yield sig-
nificant bacterial growth on quantitative culture. Further
investigations revealed presence of yeast cells in these
samples, suggesting a fungal infection. Some urine sam-
ples did not yield any significant findings using our cri-
teria despite symptoms. We think these symptoms were
due to obstetric or other gynecological diseases that the
study did not set out to investigate.
Conclusion
Staphylococcal species and E. coli are major causes of
community-acquired UTI in our setting. There is un-
acceptably high resistance to cotrimoxazole and amoxi-
cillin among uropathogens isolated in our setting.
Continued use of these drugs is likely to be associated
with a high risk of treatment failure. The recommenda-
tions of the Uganda Clinical Guidelines, 2010 are not in
tandem with the situation obtaining on the ground in
Gulu district. There is need to formulate an appropriate
hospital antibiotic policy for the treatment of UTI in our
setting. In the meantime, clinicians should take these
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findings into account whenever prescribing empirically
for UTI. We recommend that either gentamicin or
amoxicillin-clavulanate be used for empirical treatment
of UTI in our setting.
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